TPCA1, however, qualified as a suitable NFκB inhibitor in HNSCC in all experiments and all cell lines by four positive qualities: (1) Proliferation was inhibited by low μM range concentrations of TPCA1; (2) TNFα-induced IL-8 secretion was blocked by TPCA1; (3) HNSCC cells were sensitised to TNFα-induced cell death by TPCA1; and (4) TPCA1 did not interfere with FasL-mediated apoptosis. This evidence concerns the gene CXCL8 and head and neck squamous cell carcinoma.